Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Inflamm Bowel Dis. 2015 May;21(5):996–1005. doi: 10.1097/MIB.0000000000000339

TABLE 1.

Clinical characteristics of patients for microRNA profiling.

Clinical characteristics 1* 2* 3* 4 5* 6 7* 8* 9* 10*
Diagnosis UC UC UC UC UC No IBD No IBD No IBD No IBD No IBD
IBD Treatment Naïve No No No Yes Yes N/A N/A N/A N/A N/A
Age at collection 16 17 16 18 14 18 7 10 18 16
Gender Female Male Female Male Female Male Male Female Male Female
Gross sigmoid disease Yes Yes Yes N/A Yes N/A N/A N/A N/A No
Microscopic Sigmoid
inflammation		 Yes Yes Yes N/A Yes N/A N/A N/A N/A Yes, focal
active, no
chronicity
IBD Flare (clinical) Yes No Yes N/A Yes N/A N/A N/A N/A N/A
Paris Disease Location (UC)a E1 E4 E2 N/A E3 N/A N/A N/A N/A N/A
UC Paris Disease severityb S0 S1 S0 N/A S1 N/A N/A N/A N/A N/A
Paris Age at IBD Diagnosisc A1a A2 A1b N/A A1b N/A N/A N/A N/A N/A
IBD Medications Mesalamine,
prednisone		 Prednisone,
mesalamine,
metronidazole		 Mesalamine,
balsalazide		 None None N/A N/A N/A N/A N/A
PUCAId (on day of collection) 30, PUCAI 0, PUCAI 35, PUCAI N/A 70, PUCAI N/A N/A N/A N/A N/A
a

E1 - Ulcerative proctitis, E2 - Left sided (distal to splenic flexure), E3 - Extensive (hepatic flexure distally), E4 - Pancolitis (proximal to hepatic fixture), N/A: Not available or not applicable (if no IBD)

b

S0: never severe, S1: ever severe (PUCAI > or = 65 ever), N/A: Not available or Not applicable (if no IBD)

c

A1a: 0–9 years old (yo), A1b: 10–16 yo, A2: >16 yo, N/A = Not available or Not applicable (if no IBD)

d

Pediatric Ulcerative Colitis Activity Index

*

Samples used for subsequent validation by rt-PCR